Peking University, China
Shixuan Peng is an emerging clinical researcher and medical scholar specializing in anesthesiology and oncology. With a foundational background in clinical medicine and growing expertise in cancer-related translational research, Peng has contributed extensively to peer-reviewed publications, particularly in oncology, critical care, and molecular medicine. He is known for his analytical skills in handling large clinical datasets and his strong command of scientific writing. As a first and corresponding author on numerous high-impact papers, Peng has explored diverse research topics such as DNA methylation in female tumors, mortality predictors in critical care, and immunotherapy mechanisms. Actively engaged in collaborative studies with renowned institutions, he integrates basic science with clinical outcomes, aiming to improve precision diagnostics and treatment strategies. Alongside his academic pursuits, he has reviewed for multiple international journals and mentored by respected faculty, affirming his growing impact in the scientific community.
Profile
Scopus
Scholar
🎓 Education
Shixuan Peng pursued his undergraduate degree in Anesthesiology at the University of South China from 2017 to 2022, where he developed a solid clinical foundation and early exposure to research in perioperative care. Currently, he is completing his Master’s in Oncology at the same university (2022–2025), where his academic focus has transitioned toward cancer biology, clinical trials, and evidence-based treatment strategies. During his postgraduate studies, Peng engaged in extensive laboratory work and advanced statistical modeling for clinical outcomes research. He has also honed his skills in molecular techniques such as PCR, western blotting, and flow cytometry, guided by prominent mentors at Central South University’s Xiangya Hospital. His formal education is further enriched by hands-on experience in bioinformatics and the analysis of critical care databases like MIMIC-III and MIMIC-IV. His academic training has been tailored to bridge the gap between translational research and clinical application, with an emphasis on cancer immunology and molecular oncology.
💼 Experience
Shixuan Peng has diverse academic and clinical research experience, serving as a research assistant under Professors Hong Liu and Xingli Zhang at Xiangya Hospital, Central South University, where he investigates the NUDT21 gene’s role in pyroptosis. Since 2023, he has worked on multiple high-impact studies analyzing clinical outcomes using real-world data from ICU settings, exploring relationships between serum markers and mortality in heart failure and sepsis patients. His practical skills include clinical data analysis, molecular biology techniques, and the creation of scientific visuals. Peng’s expertise in academic writing and interpretation of large-scale datasets has positioned him as a reliable collaborator in multi-author projects. His roles have spanned project design, data cleaning, statistical analysis, and manuscript drafting. Beyond his research assistantship, Peng frequently collaborates with oncology and cardiology units, providing multidisciplinary insight. His expanding responsibilities in project management and scientific communication demonstrate his readiness for independent research leadership in clinical and translational medicine.
🏆 Awards and Honors
Although early in his academic career, Shixuan Peng has distinguished himself through scholarly excellence, becoming first or corresponding author on more than a dozen indexed journal publications in high-impact venues such as Biochim Biophys Acta, International Journal of Surgery, and Cancer Immunology, Immunotherapy. His recognition as a peer reviewer for respected journals including Frontiers in Immunology, BMC Anesthesiology, and Medicine reflects his growing authority in the field. He was selected for data mentorship programs and collaborative research under prestigious faculty at Xiangya Hospital, which signifies academic trust in his abilities. While not formally listed with national awards yet, his consistent publication in Q1/Q2 journals and co-leadership on systematic reviews and meta-analyses represent critical accomplishments. His ongoing involvement in cutting-edge cancer immunotherapy projects and predictive modeling in cardiovascular diseases positions him for future accolades in precision medicine and clinical epidemiology. His rapid progression underscores his potential for future academic and research awards.
🔬 Research Focus
Shixuan Peng’s research focuses on oncology, critical care outcomes, and translational medicine, with a strong emphasis on clinical epidemiology and molecular diagnostics. He has contributed significantly to understanding the prognostic value of biomarkers such as serum sodium, red blood cell distribution width, and serum anion gap in ICU patients. In oncology, his interests lie in tumor immunotherapy, cancer-related pain management, and DNA methylation testing in gynecologic tumors. Peng also investigates treatment response predictors in KRAS-mutated lung cancer and hepatocellular carcinoma, often using retrospective analyses of large clinical datasets like MIMIC-III and IV. He is engaged in studies exploring the integration of immune checkpoint inhibitors into multimodal strategies for liver cancer. His work blends clinical informatics with lab-based insights, including the role of genes like NUDT21 in cell death mechanisms. With experience in scientific visualization and academic writing, his research aims to translate lab findings into meaningful clinical applications.
Conclusion
Shixuan Peng is a highly capable and driven early-career researcher whose contributions to oncology and clinical science are both substantial and timely. His publishing record, technical skill set, and interdisciplinary focus position him as a deserving candidate for the Excellence in Research Award. With continued development in research leadership and clinical integration, he is poised to make sustained, high-impact contributions to the medical research community.
Publication
-
Bifidobacterium modulation of tumor immunotherapy and its mechanism | 2024 | B Pei, S Peng, C Huang, F Zhou | Cancer Immunology, Immunotherapy 73(5), 94
-
Relationship between serum sodium levels and all-cause mortality in congestive heart failure patients: a retrospective cohort study based on the MIMIC-III database | 2023 | S Peng, J Peng, L Yang, W Ke | Frontiers in Cardiovascular Medicine 9, 1082845
-
Association between red blood cell distribution width and all-cause mortality in unselected critically ill patients: Analysis of the MIMIC-III database | 2023 | S Peng, W Li, W Ke | Frontiers in Medicine 10, 1152058
-
The association between serum anion gap and all‐cause mortality of unselected adult patients: A retrospective cohort study of >20,000 patients | 2023 | X Ji, S Peng | Journal of Clinical Laboratory Analysis 37(1), e24818
-
The relationship between preoperative anemia and length of hospital stay among patients undergoing radical surgery for esophageal carcinoma: a single-centre retrospective study | 2023 | Z Zheng, S Peng, J Yang, W Ke | BMC Anesthesiology 23(1), 322
-
Potential applications of DNA methylation testing technology in female tumors and screening methods | 2023 | S Peng, X Zhang, Y Wu | Biochimica et Biophysica Acta (BBA) – Reviews on Cancer 1878(5), 188941
-
The application and therapeutic effect of botulinum toxin type A (BTX-A) in the treatment of patients with pain after cancer treatment: a systematic review and meta-analysis | 2024 | S Li, S Peng, F Chen, B Zeng, Z Zhang, Z Zhang | International Journal of Surgery 110(2), 1215–1223
-
Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics | 2023 | Y Zhang, F Zeng, S Peng, Y Chen, W Jiang, Z Wang, L Deng, Z Huang, … | Expert Review of Respiratory Medicine 17(9), 743–751
-
The relationship between serum anion gap levels and short-, medium-, and long-term all-cause mortality in ICU patients with congestive heart failure: a retrospective cohort study | 2024 | S Peng, Q Chen, W Ke, Y Wu | Acta Cardiologica 79(6), 705–719
-
Predicting In-Hospital Mortality in Myocardial Infarction: A Nomogram-Based Retrospective Analysis of the MIMIC-IV Database | 2025 | S Peng, Q Chen, W Ke, Y Wu | Vascular Health and Risk Management, 461–476
-
Combining Cetuximab and Immunotherapy for Treating MSS/pMMR Colorectal Cancer: Current Evidence and Challenges | 2025 | B Pei, S Peng, W Chen, L Lai, F Zhou | Technology in Cancer Research & Treatment 24, 15330338251334209
-
Perspectives on cancer therapy—synthetic lethal precision medicine strategies, molecular mechanisms, therapeutic targets and current technical challenges | 2025 | S Peng, M Long, Q Chen, Z Yin, C Zeng, W Zhang, Q Wen, X Zhang, W Ke, … | Cell Death Discovery 11(1), 179
-
Mendelian randomization analyses support causal relationships between HPV infection and colorectal cancer | 2024 | B Pei, P Liu, S Peng, F Zhou | Discover Oncology 15(1), 795
-
Renewed call for action: Highlight negative results to improve science | 2024 | B Pei, H Yang, S Peng | Clinics 79, 100426
-
ICIs in hepatocellular carcinoma: A comprehensive analysis of path forward for multimodal treatment strategies | 2024 | S Peng, Q Chen, Y Wu | Hepatology Communications 8(8), e0509